AMLX · XBRL financial data

Amylyx Pharmaceuticals financial statements, every fiscal year

The same tables from 4 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (AMLX's year ends in late December)

In thousands of dollars	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue	22,230	380,786	—	—
Revenue from contracts with customers	22,230	380,786	87,371	0
Cost of goods and services sold	2,993	25,441	5,953	0
Research and development	93,450	128,187	104,084	90,404
Selling, general and administrative	127,128	188,356	114,331	62,887
Operating income (loss)	(201,341)	38,802	(314,731)	(153,291)
Interest income	4,291	16,155	13,809	9,302
Other income (expense)	(551)	(660)	(1,214)	(700)
Income tax expense (benefit)	774	5,026	(393)	46
Net income (loss)	(198,375)	49,271	(301,743)	(144,735)
Earnings per share, basic USD per share	(3.39)	0.73	(4.43)	(1.53)
Earnings per share, diluted USD per share	(3.39)	0.70	(4.43)	(1.53)
Weighted average shares, basic thousands of shares	58,496	67,234	68,142	94,566
Weighted average shares, diluted thousands of shares	58,496	69,991	68,142	94,566

Fiscal years (AMLX's year ends in late December)

In thousands of dollars	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	62,526	170,201	77,391	226,651
Short-term investments	284,419	201,161	—	—
Marketable securities	—	201,161	99,110	90,328
Accounts receivable	15,306	40,050	447	88
Inventory	9,769	38,323	—	—
Prepaid and other current assets	10,113	14,931	12,484	6,604
Total current assets	382,133	464,666	189,432	323,671
Property and equipment, net	2,611	2,686	961	310
Right-of-use asset	5,524	3,725	1,771	5,181
Total assets	391,453	517,454	193,634	332,645
Accounts payable	6,257	22,061	2,939	3,519
Accrued liabilities	38,312	57,724	23,949	17,910
Total current liabilities	46,609	82,042	28,406	22,688
Lease liability, non-current	4,237	1,980	463	4,698
Total liabilities	50,846	84,022	28,869	27,386
Accumulated deficit	(354,220)	(304,949)	(606,692)	(751,427)
Total stockholders' equity	340,607	433,432	164,765	305,259
Total liabilities and equity	391,453	517,454	193,634	332,645
Common shares outstanding (cover page) thousands of shares	66,716	67,782	88,602	110,537

Fiscal years (AMLX's year ends in late December)

In thousands of dollars	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(198,375)	49,271	(301,743)	(144,735)
Stock-based compensation	21,714	37,161	33,038	27,645
Net cash from operating activities	(179,871)	11,919	(167,647)	(123,343)
Purchases of property and equipment	2,526	1,241	157	138
Net cash from investing activities	(238,988)	92,053	75,654	14,039
Net cash from financing activities	431,789	3,543	348	257,029
Net change in cash	12,865	107,675	(92,083)	148,799

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Amylyx Pharmaceuticals	240,095	not reported	(33,674)*	128.6M	22.6 quarters	Q3 FY26 10-QSep 30, 2026
Elite Pharmaceuticals	39,416	32,355	10,070	1.1B	—	Q1 FY27 10-QJun 30, 2026
Iovance Biotherapeutics	57,934	121,469	(4,470)*	462.7M	7.3 quarters	Q3 FY26 10-QSep 30, 2026
KalVista Pharmaceuticals	213,768	40,863	(14,455)	53.2M	19.7 quarters	Q1 FY26 10-QMar 31, 2026
Opko Health	384,036	65,414	(36,315)*	742.5M	10.8 quarters	Q3 FY26 10-QSep 30, 2026
Kura Oncology	70,242	20,874	(62,549)*	89.0M	8.3 quarters	Q2 FY26 10-QJun 30, 2026
Myriad Genetics	107,100	202,700	(6,500)*	95.9M	10.5 quarters	Q3 FY26 10-QSep 30, 2026
Savara	41,800	not reported	(29,747)*	205.5M	5.8 quarters	Q2 FY26 10-QJun 30, 2026
Xencor	59,622	116,520	2,642*	75.0M	—	Q3 FY26 10-QSep 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.

Data on this page was fetched Nov 7, 2026, 12:27 PM ET. The filing on SEC.gov is the record.